PerkinElmer Expands Diagnostics Offerings Worldwide with Chinese Acquisition

(Waltham, MA, USA) has purchased Sym-Bio Lifescience (Shanghai, China), provider of diagnostics instruments and related reagents, in a cash transaction equivalent to US$63.7 million. The addition of Sym-Bio's infectious disease products complements PerkinElmer's worldwide position in prenatal and neonatal screening and provides a new line of diagnostics for expansion of the company's regional and global offerings.

As part of the acquisition, PerkinElmer gains access to substantial manufacturing plant capacity in Shanghai and the surrounding area, where the company will be able to expand local production capabilities for a number of PerkinElmer products in China, in addition to the diagnostics portfolio.

Sym-Bio Lifescience supplies diagnostics to hospitals in China, particularly in the area of infectious diseases, and this represents a major addition to PerkinElmer's diagnostics portfolio. The acquisition doubles PerkinElmer's access to the hospitals market segment in China, offering a larger base from which to expand its prenatal and newborn screening business. It also provides PerkinElmer with a significant local manufacturing and R&D base.

PerkinElmer develops diagnostic and research instrumentation technologies as well as clinical resources and support services, to fight illness, provide accurate medical insight, and develop therapies more quickly.

Sym-Bio Lifescience's offerings include optical mechanical technology, electrical automation, chemical synthesis, and cloned antibodies preparation. Sym-Bio developed a time-resolved fluorescence (TRF) detection system, as well as a TRF in vitro diagnostic kit.

Related Links:
PerkinElmer, Inc.
Sym-Bio Lifescience